Edwards Lifesciences Co. (NYSE:EW) VP Sells $466,450.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Stock Performance

Shares of EW opened at $92.85 on Friday. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The company has a market cap of $55.95 billion, a price-to-earnings ratio of 40.02, a price-to-earnings-growth ratio of 3.36 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The firm has a fifty day moving average of $88.86 and a 200-day moving average of $86.26.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently bought and sold shares of EW. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $28,000. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $28,000. Turtle Creek Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $34,000. Riverview Trust Co bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $34,000. Finally, Pingora Partners LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EW. Deutsche Bank Aktiengesellschaft upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $86.00 to $103.00 in a research note on Tuesday, May 14th. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. Oppenheimer lifted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Finally, Evercore ISI lifted their price objective on shares of Edwards Lifesciences from $89.00 to $91.00 and gave the stock an “in-line” rating in a report on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $95.24.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.